Education
About Us
Working with TipRanks
Follow Us
Lantheus (LNTH)
NASDAQ:LNTH
LNTH Stock Chart & Stats
Day’s Range― - ―
52-Week Range$62.59 - $126.89
Previous CloseN/A
Volume177.90K
Average Volume (3M)851.55K
Market Cap
$6.89B
Enterprise Value$5.90B
Total Cash (Recent Filing)$33.32M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)23.0
Beta0.42
Next Earnings
May 01, 2025EPS Estimate
1.64Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)4.37
Shares Outstanding68,480,310
10 Day Avg. Volume946,396
30 Day Avg. Volume851,552
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)N/A
Price to Sales (P/S)4.36
Price to Cash Flow (P/CF)10.60
P/FCF Ratio6.50
Enterprise Value/Market Cap0.86
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit5.97
Enterprise Value/Ebitda11.45
Forecast
1Y Price Target
$127.13Price Target Upside27.68% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
---
Lantheus News
PremiumCompany Announcements
Lantheus Completes Acquisition of Evergreen Theragnostics
PremiumCompany Announcements
Lantheus Holdings Inc. Reports Strong Growth and Strategic Moves
PremiumCompany Announcements
Lantheus Holdings Faces Uncertainty Amid Potential PET Scanner Shortage
---
Bulls Say, Bears Say
Bulls Say
Financial Performance4Q results again exceeded expectations on the top and bottom lines, as did the initial 2025 outlook.
Market PositionLantheus Holdings cements its position as a leader in the radiopharma space with a series of strategic acquisitions and investments.
Revenue GrowthLantheus' 4Q24 total revenues came in slightly above consensus, driven by significant growth in Pylarify and Definity sales.
Bears Say
Earnings ForecastThe updated earnings per share for the full year 2025 are lower than previous estimates.
Revenue GuidanceFY25 total revenue guidance was slightly below consensus expectations.
Valuation ConcernsThe stock is trading at a significant discount, with shares at ~12.5x EV/EBITDA, representing a -20% discount to its blended peer set.
---
Ownership Overview
2.12% Insiders
38.84% Mutual Funds
2.68% Other Institutional Investors
28.73% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
LNTH FAQ
What was Lantheus’s price range in the past 12 months?
Lantheus lowest stock price was $62.59 and its highest was $126.89 in the past 12 months.
What is Lantheus’s market cap?
Lantheus’s market cap is $6.89B.
When is Lantheus’s upcoming earnings report date?
Lantheus’s upcoming earnings report date is May 01, 2025 which is in 7 days.
How were Lantheus’s earnings last quarter?
Lantheus released its earnings results on Feb 26, 2025. The company reported $1.59 earnings per share for the quarter, beating the consensus estimate of $1.543 by $0.047.
Is Lantheus overvalued?
According to Wall Street analysts Lantheus’s price is currently Undervalued.
Does Lantheus pay dividends?
Lantheus does not currently pay dividends.
What is Lantheus’s EPS estimate?
Lantheus’s EPS estimate is 1.64.
How many shares outstanding does Lantheus have?
Lantheus has 68,480,310 shares outstanding.
What happened to Lantheus’s price movement after its last earnings report?
Lantheus reported an EPS of $1.59 in its last earnings report, beating expectations of $1.543. Following the earnings report the stock price went up 16.49%.
Which hedge fund is a major shareholder of Lantheus?
Currently, no hedge funds are holding shares in LNTH
---
Lantheus Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$127.13 (27.68% Upside)
$127.13 (27.68% Upside)
Blogger Sentiment
Bullish
LNTH Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 2.2M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $281.5 over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.3%
Last 30 Days ▼ 2.0%
Last 30 Days ▼ 2.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
57.68%
12-Months-Change
Fundamentals
Return on Equity
32.82%
Trailing 12-Months
Asset Growth
22.04%
Trailing 12-Months
Company Description
Lantheus
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. It also develops flurpiridaz F 18 to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in pediatric and adults; PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. The company serves radio pharmacies, distributors, integrated delivery networks, hospitals, clinics, and group practices. It has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; Curium; Bayer AG; CytoDyn Inc.; ROTOP; FUJIFILM; Regeneron Pharmaceuticals, Inc.; and POINT Biopharma US Inc. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.
---
LNTH Company Deck
---
LNTH Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Lantheus reported strong revenue growth driven by Pylarify and DEFINITY, alongside strategic acquisitions expected to bolster future growth. However, challenges include increased operating expenses and a net loss for the quarter. Despite these challenges, the company remains optimistic about its pipeline and strategic direction.Read More>---
LNTH Revenue Breakdown
65.91% Radiopharmaceutical oncology
30.09% Precision diagnostics
4.00% Strategic Partnerships and other revenue
---
LNTH Stock 12 Month Forecast
Average Price Target
$127.13
▲(27.68% Upside)
Technical Analysis
Dr Reddy's Laboratories
―
Viatris
―
Neurocrine
―
Perrigo Company
―
Teva Pharmaceutical
―
Best Analysts Covering LNTH
1 Year
1 Year Success Rate
23/30 ratings generated profit
1 Year Average Return
+53.05%
reiterated a buy rating 2 months ago
Copying Richard Newitter's trades and holding each position for 1 Year would result in 76.67% of your transactions generating a profit, with an average return of +53.05% per trade.
---